Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3642
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Melphalan and Prednisone Versus Melphalan, Prednisone and Thalidomide for Elderly and/or Transplant Ineligible Patients With Multiple Myeloma: A Meta-Analysis

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Phase I/Ii Study of Carfilzomib, Bendamustine, and Dexamethasone (CBD) in Patients With Newly Diagnosed Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2020English

First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials

Haematologica
Hematology
2019English

Pcn340 - Real-World Usage of Bortezomib in Combination With Melphalan and Prednisone (Vmp) as Frontline (Fl) Treatment in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients Across Eu5 Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

High-Dose BCNU/Melphalan Conditioning Regimen Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2017English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy